guest ::
| Home > Publications database > Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer. > print |
| Home > Publications database > Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer. > print |
| 001 | 294365 | ||
| 005 | 20241217153011.0 | ||
| 024 | 7 | _ | |a 10.1172/JCI179501 |2 doi |
| 024 | 7 | _ | |a pmid:39470729 |2 pmid |
| 024 | 7 | _ | |a 0021-9738 |2 ISSN |
| 024 | 7 | _ | |a 1558-8238 |2 ISSN |
| 024 | 7 | _ | |a altmetric:169862355 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-02198 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Nelson, Brad H |b 0 |
| 245 | _ | _ | |a Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer. |
| 260 | _ | _ | |a Ann Arbor, Mich. |c 2024 |b ASCJ |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1734445773_9038 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2024 Oct 29;134(24):e179501 |
| 520 | _ | _ | |a Despite an overall poor prognosis, about 15% of patients with advanced-stage tubo-ovarian high-grade serous carcinoma (HGSC) survive ten or more years after standard treatment.We evaluated the tumor microenvironment of this exceptional, understudied group using a large international cohort enriched for long-term survivors (LTS; 10+ years; n = 374) compared to medium-term (MTS; 5-7.99 years; n = 433) and short-term survivors (STS; 2-4.99 years; n = 416). Primary tumor samples were immunostained and scored for intra-epithelial and intra-stromal densities of 10 immune-cell subsets (including T cells, B cells, plasma cells, myeloid cells, PD-1+ cells, and PD-L1+ cells) and epithelial content.Positive associations with LTS compared to STS were seen for 9/10 immune-cell subsets. In particular, the combination of intra-epithelial CD8+ T cells and intra-stromal B cells showed near five-fold increased odds of LTS compared to STS. All of these associations were stronger in tumors with high epithelial content and/or the C4/Differentiated molecular subtype, despite immune-cell densities generally being higher in tumors with low epithelial content and/or the C2/Immunoreactive molecular subtype.The tumor microenvironment of HGSC long-term survivors is distinguished by the intersection of T and B cell co-infiltration, high epithelial content and C4/Differentiated molecular subtype, features which may inspire new approaches to immunotherapy.Ovarian Cancer Research Program (OCRP) of the Congressionally Directed Medical Research Program (CDMRP), U.S. Department of Defense (DOD); American Cancer Society; BC Cancer Foundation; Canada's Networks of Centres of Excellence; Canadian Cancer Society; Canadian Institutes of Health Research; Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, Cancer Foundation of Western Australia; Cancer Institute NSW; Cancer Research UK; Deutsche Forschungsgesellschaft; ELAN Funds of the University of Erlangen-Nuremberg; Fred C. and Katherine B. Andersen Foundation; Genome BC; German Cancer Research Center; German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research; Instituto de Salud Carlos III; Mayo Foundation; Minnesota Ovarian Cancer Alliance; Ministerio de Economía y Competitividad; MRC; National Center for Advancing Translational Sciences; National Health and Medical Research Council of Australia (NHMRC); Ovarian Cancer Australia; Peter MacCallum Foundation; Sydney West Translational Cancer Research Centre; Terry Fox Research Institute; The Eve Appeal (The Oak Foundation); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge; University of Pittsburgh School of Medicine; U.S. National Cancer Institute of the National Institutes of Health; VGH & UBC Hospital Foundation; Victorian Cancer Agency. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Cancer |2 Other |
| 650 | _ | 7 | |a Cellular immune response |2 Other |
| 650 | _ | 7 | |a Epidemiology |2 Other |
| 650 | _ | 7 | |a Immunology |2 Other |
| 650 | _ | 7 | |a Oncology |2 Other |
| 700 | 1 | _ | |a Hamilton, Phineas T |b 1 |
| 700 | 1 | _ | |a Phung, Minh Tung |b 2 |
| 700 | 1 | _ | |a Milne, Katy |b 3 |
| 700 | 1 | _ | |a Harris, Bronwyn |b 4 |
| 700 | 1 | _ | |a Thornton, Shelby |b 5 |
| 700 | 1 | _ | |a Stevens, Donald Li |b 6 |
| 700 | 1 | _ | |a Kalaria, Shreena |b 7 |
| 700 | 1 | _ | |a Singh, Karanvir |b 8 |
| 700 | 1 | _ | |a Laumont, Céline M |b 9 |
| 700 | 1 | _ | |a Moss, Elena |b 10 |
| 700 | 1 | _ | |a Alimujiang, Aliya |b 11 |
| 700 | 1 | _ | |a Meagher, Nicola S |b 12 |
| 700 | 1 | _ | |a Bolithon, Adelyn |b 13 |
| 700 | 1 | _ | |a Fereday, Sian |b 14 |
| 700 | 1 | _ | |a Kennedy, Catherine J |b 15 |
| 700 | 1 | _ | |a Hendley, Joy |b 16 |
| 700 | 1 | _ | |a Ariyaratne, Dinuka |b 17 |
| 700 | 1 | _ | |a Alsop, Kathryn |b 18 |
| 700 | 1 | _ | |a Traficante, Nadia |b 19 |
| 700 | 1 | _ | |a Goode, Ellen L |b 20 |
| 700 | 1 | _ | |a Karnezis, Anthony N |b 21 |
| 700 | 1 | _ | |a Shen, Hui |b 22 |
| 700 | 1 | _ | |a Richardson, Jean |b 23 |
| 700 | 1 | _ | |a McKinnon Deurloo, Cindy |b 24 |
| 700 | 1 | _ | |a Chase, Anne |b 25 |
| 700 | 1 | _ | |a Grout, Bronwyn |b 26 |
| 700 | 1 | _ | |a Doherty, Jennifer A |b 27 |
| 700 | 1 | _ | |a Harris, Holly R |b 28 |
| 700 | 1 | _ | |a Cushing-Haugen, Kara L |b 29 |
| 700 | 1 | _ | |a Anglesio, Michael S |b 30 |
| 700 | 1 | _ | |a Heinze, Karolin |b 31 |
| 700 | 1 | _ | |a Huntsman, David |b 32 |
| 700 | 1 | _ | |a Talhouk, Aline |b 33 |
| 700 | 1 | _ | |a Hanley, Gillian E |b 34 |
| 700 | 1 | _ | |a Alsop, Jennifer |b 35 |
| 700 | 1 | _ | |a Jimenez-Linan, Mercedes |b 36 |
| 700 | 1 | _ | |a Pharoah, Paul Dp |b 37 |
| 700 | 1 | _ | |a Boros, Jessica |b 38 |
| 700 | 1 | _ | |a Brand, Alison H |b 39 |
| 700 | 1 | _ | |a Harnett, Paul R |b 40 |
| 700 | 1 | _ | |a Sharma, Raghwa |b 41 |
| 700 | 1 | _ | |a Hecht, Jonathan L |b 42 |
| 700 | 1 | _ | |a Sasamoto, Naoko |b 43 |
| 700 | 1 | _ | |a Terry, Kathryn L |b 44 |
| 700 | 1 | _ | |a Karlan, Beth Y |b 45 |
| 700 | 1 | _ | |a Lester, Jenny |b 46 |
| 700 | 1 | _ | |a Carney, Michael E |b 47 |
| 700 | 1 | _ | |a Goodman, Marc T |b 48 |
| 700 | 1 | _ | |a Hernandez, Brenda Y |b 49 |
| 700 | 1 | _ | |a Wilkens, Lynne R |b 50 |
| 700 | 1 | _ | |a Behrens, Sabine |0 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea |b 51 |u dkfz |
| 700 | 1 | _ | |a Turzanski Fortner, Renée |0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |b 52 |u dkfz |
| 700 | 1 | _ | |a Fasching, Peter A |b 53 |
| 700 | 1 | _ | |a Bisinotto, Christiani |b 54 |
| 700 | 1 | _ | |a Candido Dos Reis, Francisco José |b 55 |
| 700 | 1 | _ | |a Ghatage, Prafull |b 56 |
| 700 | 1 | _ | |a Köbel, Martin |b 57 |
| 700 | 1 | _ | |a Elishaev, Esther |b 58 |
| 700 | 1 | _ | |a Modugno, Francesmary |b 59 |
| 700 | 1 | _ | |a Cook, Linda S |b 60 |
| 700 | 1 | _ | |a Le, Nhu D |b 61 |
| 700 | 1 | _ | |a Gentry-Maharaj, Aleksandra |b 62 |
| 700 | 1 | _ | |a Menon, Usha |b 63 |
| 700 | 1 | _ | |a García, María J |b 64 |
| 700 | 1 | _ | |a Rodriguez-Antona, Cristina |b 65 |
| 700 | 1 | _ | |a Farrington, Kyo M |b 66 |
| 700 | 1 | _ | |a Kelemen, Linda E |b 67 |
| 700 | 1 | _ | |a Kommoss, Stefan |b 68 |
| 700 | 1 | _ | |a Staebler, Annette |b 69 |
| 700 | 1 | _ | |a Garsed, Dale W |b 70 |
| 700 | 1 | _ | |a Brenton, James D |b 71 |
| 700 | 1 | _ | |a Piskorz, Anna M |b 72 |
| 700 | 1 | _ | |a Bowtell, David Dl |b 73 |
| 700 | 1 | _ | |a DeFazio, Anna |b 74 |
| 700 | 1 | _ | |a Ramus, Susan J |b 75 |
| 700 | 1 | _ | |a Pike, Malcolm C |b 76 |
| 700 | 1 | _ | |a Pearce, Celeste Leigh |b 77 |
| 773 | _ | _ | |a 10.1172/JCI179501 |0 PERI:(DE-600)2018375-6 |n 24 |p e179501 |t The journal of clinical investigation |v 134 |y 2024 |x 0021-9738 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:294365 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 51 |6 P:(DE-He78)6b04712f3afe72044d496a25505cb1ea |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 52 |6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-02-14T21:03:14Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-02-14T21:03:14Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Peer review |d 2023-02-14T21:03:14Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2023-02-14T21:03:14Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-22 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-22 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J CLIN INVEST : 2022 |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-22 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-22 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b J CLIN INVEST : 2022 |d 2023-10-22 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-10-22 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-10-22 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|